SCHEMBL3017592

SCHEMBL3017592

CN1CC(c2ccccc2)([N+](=O)[O-])CCC1=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
SRD5A1 P18405 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
DRD4 P21917 1/20 0.35
OPRM1 P35372 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GRIN1 Q05586 2/20 0.35
GRIN2A Q12879 2/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
AKR1C1 Q04828 1/20 0.35
CYP2C19 P33261 1/20 0.35
CYP2C9 P11712 1/20 0.34
BRD4 O60885 3/20 0.33
SRD5A2 P31213 2/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3023214 0.86 CYP19A1 (0.43)
SCHEMBL3020063 0.84 HSD11B1 (0.36) ALDH1A1MEN1KMT2A
SCHEMBL3033884 0.84 KDM4E (0.36) ALDH1A1OPRM1MEN1KMT2A
SCHEMBL3018057 0.76 ALDH1A1 (0.36) ALDH1A1L3MBTL1MEN1KMT2ACYP2C19
SCHEMBL3020089 0.75 L3MBTL1 (0.40) ALDH1A1L3MBTL1SMN1; SMN2OPRM1MEN1
SCHEMBL3023013 0.74 ALDH1A1 (0.37) ALDH1A1L3MBTL1SMN1; SMN2DRD4OPRM1
SCHEMBL3023010 0.74 ALDH1A1 (0.37) ALDH1A1L3MBTL1SMN1; SMN2DRD4OPRM1
SCHEMBL7894208 0.74 ALDH1A1 (0.37) ALDH1A1L3MBTL1SMN1; SMN2DRD4OPRM1
SCHEMBL19797989 0.73 ALDH1A1 (0.36) ALDH1A1L3MBTL1OPRM1MEN1KMT2A
SCHEMBL3023502 0.73 ALDH1A1 (0.36) ALDH1A1L3MBTL1SMN1; SMN2OPRM1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067911-B2 Piperidine derivatives HOFFMANN-LA ROCHE INC. (US) 2015-06-30 US disclosed
US-9067911-B2 Piperidine derivatives HOFFMANN-LA ROCHE INC. (US) 2015-06-30 US disclosed
EP-2391603-B1 AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
US-20130158050-A1 PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US disclosed
US-20130158050-A1 PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US disclosed
EP-2391603-A1 AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-07 EP disclosed
US-20100197715-A1 PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-08-05 US disclosed
US-20100197715-A1 PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-08-05 US disclosed
WO-2010086251-A1 AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158050-A1 PIPERIDINE DERIVATIVES GRIN1, GRIN2A, GRIN2C ALDH1A1 55/4885SRD5A1 450/4885L3MBTL1 4609/4885
US-20100197715-A1 PIPERIDINE DERIVATIVES GRIN1, GRIN2A, GRIN2C ALDH1A1 55/4885SRD5A1 450/4885L3MBTL1 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.